Scleroderma: A treatable disease

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 11, 2003, Pages 954-968

  Korn, Joseph H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BONE MORPHOGENETIC PROTEIN 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; CEFALEXIN; CIPROFLOXACIN; CREATININE; CYCLOPHOSPHAMIDE; DICLOXACILLIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTON PUMP INHIBITOR; SILDENAFIL; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT;

ARTICLE; ASPIRATION PNEUMONIA; BLOOD PRESSURE MONITORING; BLOOD VESSEL INJURY; BRONCHIECTASIS; CARDIOVASCULAR DISEASE; CHRONIC DIARRHEA; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FIBROSING ALVEOLITIS; FIBROSIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LASER SURGERY; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION TEST; PLEURA DISEASE; PLEURA EFFUSION; PROTEINURIA; PULMONARY HYPERTENSION; QUALITY OF LIFE; RAYNAUD PHENOMENON; SCLERODERMA; SKIN MANIFESTATION; SKIN ULCER; STOMACH ANTRUM VASCULAR ECTASIA; SUPERINFECTION; SURVIVAL RATE; SYNDROME CREST; TREATMENT PLANNING; URINALYSIS; VASCULAR DISEASE; VASOCONSTRICTION; WARMING;

EID: 0344466712     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.11.954     Document Type: Article

References (9)

1. Korn JH. Pathogenesis of systemic sclerosis (scleroderma). In: Koopman WJ, editor. Arthritis and Allied Conditions: A Textbook of Rheumatology. 14th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1643-1654.
2. Simms RW, Korn JH. Systemic sclerosis: the spectrum, immunopathogenesis, clinical features and treatment. In: Adu D, Emery P, Madaio M, editors: Rheumatology and the Kidney. Oxford: Oxford University Press, 2001:275-292.
3. White B, Morre WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954.
4. Du L, Sullivan MS, Chu D, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348:500-509.
5. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425-434.
6. Olschewski H, Simonneau G, Galie N, et al for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329.
7. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358:1119-1123.
8. Rubin LJ, Badesch DB, Barst RJ, et al for the Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group. Bosentan therapy for pulmonary arterial hypertension (published correction appears in N Engl J Med 2002; 346:16). N Engl J Med 2002; 346:896-903.
9. Simms RW, Korn JH. Cytokine-directed therapy in scleroderma: rationale, current status, and the future. Curr Opin Rheumatol 2002; 14:717-722.